A Spanish multicenter, controlled, prospective endpoint trial suggested that routinely taking blood pressure (BP)-lowering medications at bedtime, as opposed to upon waking, results in improved ambulatory BP (ABP) control and decreased occurrence of major cardiovascular disease (CVD) events. A total of 19 084 hypertensive patients (60.5 ± 13.7 years of age, 8470 women) were assigned (1:1) to take the entire daily dose of ≥1 hypertension medications at bedtime (n = 9552) or all of them upon awakening (n = 9532). At inclusion and at every scheduled clinic visit (at least annually) throughout follow-up, ABP monitoring was performed for 48 h. During the 6.3-year median patient follow-up, 1752 participants experienced the primary CVD outcome. Patients of the bedtime, compared with the upon-waking, treatment-time regimen showed significantly lower adjusted hazard ratio of the primary CVD outcome [0.55] and each of its single components, i.e. CVD death [0.44], myocardial infarction [0.66], coronary revascularization [0.60], heart failure [0.58], and stroke [0.51]. Progressive decrease in the asleep systolic BP mean during the follow-up was the most significant predictor of reduced CVD risk. The results are consistent with previous trials and document that bedtime hypertension therapy is at least as safe as usual upon-waking therapy. Source: https://academic.oup.com/
Restricting sugar intake during the first 1,000 days from conception was associated with a lower…
Incidental coronary artery calcium (CAC) identified on routine nongated chest CT scans predicts future coronary…
The burden of modifiable cardiovascular risk factors—not just the total number of risk factors—is strongly…
Higher blood levels of the gut microbiome-derived metabolite trimethylamine N-oxide (TMAO) were independently associated with…
Moderate consumption of naturally caffeinated beverages, particularly coffee, is generally associated with a lower risk…
To reduce the risk of cognitive decline and/or dementia specifically, the WHO just released updated…
This website uses cookies.